Jane Street
ABEO icon

Jane Street’s Abeona Therapeutics ABEO Stock Holding History

Jane Street’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
+50,400
New +$252K ﹤0.01% 9865
2025
Q4 		– Sell
-14,200
Closed -$75K – 10956
2025
Q3 		$75K Buy
14,200
+200
+1% +$1.27K ﹤0.01% 10238
2025
Q2 		$79.5K Buy
+14,000
New +$79.7K ﹤0.01% 9052

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's ABEO Position: Q3 2025 in Review

Jane Street sold out of Abeona Therapeutics (ABEO) in Q3 2025, closing a stake of 68,614 shares — an estimated $435K sold.

Jane Street first reported a position in ABEO in Q3 2018 and held it in 16 quarters. The position peaked at $732K in Q4 2024. 100 funds tracked by Wall St. Rank hold ABEO as of Q3 2025.

  • Jane Street reported no remaining Abeona Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 68,614 Abeona Therapeutics shares in Q3 2025, an estimated $435K.
  • Jane Street first reported a position in Abeona Therapeutics in Q3 2018 and held it in 16 quarters.
  • Jane Street's Abeona Therapeutics position peaked at $732K in Q4 2024.
  • 100 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.